INDEMNIFICATION AGREEMENTIndemnification Agreement • July 20th, 2023 • Talaris Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJuly 20th, 2023 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ___________________ between Tourmaline Bio, Inc., a Delaware corporation (the “Company”), and [____________] (“Indemnitee”).
LICENCE AGREEMENT between LONZA SALES AG andLicense Agreement • July 20th, 2023 • Talaris Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledJuly 20th, 2023 Company Industry JurisdictionLONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as “Lonza”),
Strategic Advisor AgreementStrategic Advisor Agreement • July 20th, 2023 • Talaris Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJuly 20th, 2023 Company Industry JurisdictionThis Advisor Agreement (the “Agreement”), dated as of May 26, 2023 (the “Effective Date”) is between Talaris Therapeutics, Inc., a Delaware corporation with a principal office address at 570 S. Preston Street, Suite 400, Louisville, KY, 40202, Louisville, KY, 40202 (the “Company”) and Scott Requadt, an independent advisor with an address at 15 Lewis Path, Wayland, MA 01778 (“Advisor”). Reference is made to the Severance Agreement and General Release between Advisor and the Company (the “Severance Agreement”), which remains in full effect.
LICENSE AGREEMENTLicense Agreement • July 20th, 2023 • Talaris Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 20th, 2023 Company Industry JurisdictionTHIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 3rd day of May, 2022 (the “Effective Date”), by and between Tourmaline Bio, LLC, a limited liability company organized and existing under the laws of Delaware with offices at Four Embarcadero, Suite 2100, San Francisco, CA 94111 (“Licensee”) and Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“Pfizer”). Licensee and Pfizer may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.